Primary progressive multiple sclerosis – case reports Case report
Article Sidebar
Main Article Content
Abstract
Primary progressive multiple sclerosis is nowadays an object of great interest among neurologists, because new opportunities to her therapy appeared. This form of multiple sclerosis is still poorly researched, but it is estimated that PPMS cases constitute 10–20% of all MS patients. PPMS is characterized by a gradual increase in spinal cord symptoms with little fluctuation, but without evident relapses. Distinct differences of disease course, with characteristic symptomatology and lesions in MRI, late onset of symptoms, cause that the PPMS requires the more discerning differential diagnosis.
On the basis of the cases reports concerning the course of this form of MS, diagnostic criteria, distinctness towards the relapsing-remitting multiple sclerosis and influence of the treatment was presented.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Lublin F.D., Reingold S.C., Cohen J.A. et al.: Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278-286.
3. Confavreux C., Vukusic S.: Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129: 606-616.
4. Thompson A.J., Polman C.H., Miller D.H. et al.: Primary progressive multiple sclerosis. Brain 1997; 120: 1085-1096.
5. Miller D.H., Leary S.M.: Primary-progressive multiple sclerosis. Lancet Neurol. 2007; 6: 903-912.
6. Kantarci O.H., Weinshenker B.G.: Natural history of multiple sclerosis. Neurol. Clin. 2005; 23: 17-38.
7. Montalban X., Hauser S.L., Kappos L. et al.; ORATORIO Study Group: Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 2017; 376(3): 209-220.
8. Sastre-Garriga J., Ingle G.T., Rovaris M. et al.: Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology 2005; 65: 633-635.
9. Geraldes R., Ciccarelli O., Barkhof F. et al.; MAGNIMS Study Group: The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat. Rev. Neurol. 2018; 14(4): 199-213.
10. Thompson A.J., Banwell B.L., Barkhof F. et al.: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17: 162-173.
11. Montalban X., Gold R., Thompson A.J. et al.: ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur. J. Neurol. 2018, 25: 215-237.
12. Brola W., Sobolewski P., Flaga S. et al.: Pierwotnie postępująca postać stwardnienia rozsianego w populacji polskich pacjentów. Aktualn. Neurol. 2017; 17(1): 5-14.
13. Brola W., Sobolewski P., Flaga S. et al.: Prevalence and incidence of multiple sclerosis in central Poland, 2010–2014. BMC Neurol. 2016; 16: 134.